Sarah Bhagat

Sarah Bhagat is a Partner at Sofinnova Investments based in Menlo Park, California, where she focuses on early-stage biopharmaceutical investments. She currently serves as a board director at Inozyme and holds board observer roles at several biotechnology startups, including Aeovian, Antiva, Neurana, and NorthSea. Her investment portfolio includes Promedior, where she was a board member prior to its acquisition by Roche for up to $1.4 billion, alongside publicly traded companies like Apellis and NextCure. Before joining Sofinnova, Bhagat worked as a Venture Fellow at Canaan Partners and completed a postdoctoral fellowship in psychiatry and neuroscience at Stanford University. She holds a PhD in Neuroscience from Yale University and previously worked as a clinical research coordinator at Massachusetts General Hospital. Her current investment focus centers on funding seed to Series C biotechnology companies developing novel therapeutics for unmet medical needs.